Dasatinib in Treating Patients With Relapsed Small Cell Lung Cancer

NCT00470054 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

44

Enrollment

NIH

Sponsor class

Conditions

Extensive Stage Small Cell Lung Cancer
Limited Stage Small Cell Lung Cancer
Recurrent Small Cell Lung Cancer

Interventions

DRUG: dasatinib

Sponsor

National Cancer Institute (NCI)